Hormonal IUDs Linked to Increased Risk of Rosacea in Women : Study
Researchers have found in a new study that Women using hormonal IUDs like Liletta and Mirena showed a higher likelihood of developing rosacea one year after insertion compared to those using nonhormonal copper IUDs.The increased risk was not observed with Skyla, a hormonal IUD that releases a lower dose of levonorgestrel.The study highlights a potential skin-related side effect associated with certain hormonal contraceptives.
Hormonal contraceptives manipulate estrogen and progesterone levels and have been associated with dermatologic side effects, including rosacea, a chronic skin condition marked by facial redness and inflammatory lesions.
This multicenter cohort study evaluated the incidence of rosacea among users of hormonal intrauterine devices (IUDs)-Liletta, Mirena, and Skyla-compared to nonhormonal copper IUD users. Women aged 18-50 who underwent IUD insertion and had a new diagnosis of rosacea (ICD-10-CM code L71) within 1, 3, or 5 years post-insertion were included. Those with prior rosacea or early IUD removal were excluded. Data were drawn from the TriNetX network. Incidence rates (IRs), incidence rate ratios (IRRs), and absolute risk differences (ARDs) were calculated, using the copper IUD group as the reference. Statistical significance (P ≤ .05) was determined via the Wald test. At 1-year postinsertion, Liletta users exhibited the highest IR of rosacea (634.28 per 100,000 person-years) with a significant IRR of 1.665 (P < .001).
Mirena users had an IR of 529.30 and an IRR of 1.389 (P < .001), while Skyla users had an IR of 409.00, but the IRR (1.074) was not significant (P = .696). At 3 years, Liletta maintained the highest IR (391.74) and a significant IRR of 1.751 (P < .001), followed by Mirena (IR 322.02, IRR 1.440, P < .001). Skyla's IRR remained non-significant. At 5 years, Liletta continued to show the highest IR (285.02) with an IRR of 1.788 (P < .001), and Mirena had an IR of 234.54 with a significant IRR of 1.472 (P < .001). Skyla's IRR remained statistically non-significant throughout all time points.
These findings suggest that Liletta and Mirena may be associated with an increased risk of developing rosacea compared to nonhormonal IUDs.
Reference:
Incidence of rosacea associated with hormonal intrauterine devices: A comparative study with nonhormonal intrauterine devices. Arza, Alexis et al. Journal of the American Academy of Dermatology, Volume 92, Issue 2, 351 - 352
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.